Spots Global Cancer Trial Database for Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor

Official Title: Dose Escalation Study of Tolerability and Pharmacokinetics of PEDylated Recombinant Human Endostatin(M2ES)in the Treatment of Advanced Solid Tumor

Study ID: NCT01260025

Conditions

Tolerability

Pharmacokinetics

Endostatin

Interventions

PEDylated Recombinant Human Endostatin

Study Description

Brief Summary: 1. MTD and DLT of M2ES 2. Pharmacokinetics of M2ES

Detailed Description: Patients received infusion of M2ES for 120 minutes weekly（d1,d8,d15）by calculated pump and underwent evaluation of vital signs including blood pressure, pulse, respiratory rate, and temperature before treatment, at intervals during infusion, and hourly for 6 hours after infusion. After infusion, patients underwent serial pharmacokinetic sampling. All patients were seen weekly during the study therapy and follow-up and underwent evaluation with physical examination including ECOG performance status, vital signs, and laboratory evaluation with complete blood count with manual differential, chemistry evaluation, prothrombin time/partial thromboplastin time, and urinalysis.